Cardio Diagnostics Inc., a company that assesses genetic and epigenetic DNA markers to monitor a patient's risk for heart disease, was recently selected as “one to watch” in this year’s inaugural Spinoff Prize, organized by Nature Research and Merck KGaA. Founded in 2017 and based at the UI Research Park in Coralville, Cardio Diagnostics focuses on human health by developing and commercializing precision medicine tools for the prevention of heart disease and stroke. The prize showcases global excellence in the commercialization of research through the creation of spinoff companies. Twelve finalists and 32 additional early-stage startups (including Cardio Diagnostics) were recognized for their ability to “translate original, high-quality scientific research into products and services that address market problems and are well positioned to make a positive impact on society.”